Kiora Pharmaceuticals Inc... (KPRX)
Kiora Pharmaceuticals Inc. (KPRX) Stock Price, Analysis & Data
| Bid | 1.84 |
| Market Cap | 11.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.99M |
| Beta | n/a |
| EPS (ttm) | -2.41 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.13 |
| P/B (ttm) | 0.72 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 3.2 |
| Volume | 37,653 |
| Avg. Volume (20D) | 24,132 |
| Open | 2.53 |
| Previous Close | 2.59 |
| Day's Range | 2.48 - 2.55 |
| 52-Week Range | 1.76 - 3.01 |
| Analyst | Buy |
| Price Target | 12 (376.19%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About KPRX
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory,...
Financial Performance
In 2025, Kiora Pharmaceuticals's revenue was 0, a decrease of -100% compared to the previous year's 16M. Earnings were -10.84M, a decrease of -401.42%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for KPRX stock is "Buy". The 12-month stock price forecast is 12, which is upside of 376.19% from the latest price.
Stock Forecasts